A Phase 2 study of pembrolizumab and ATRA in relapsed HL and B-NHL
Recruiting Phase 2 NCT06484920
Study Description
A study evaluating the combination of pembrolizumab and ATRA for the treatment of relapsed or refractory Hodgkin Lymphoma and B-Non-Hodgkin Lymphoma
Study Details
- Registry ID:
- NCT06484920
- Conditions:
- Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, B-cell Lymphoma
- Phase:
- Phase 2
- Target Enrollment:
- 24 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Study Locations (2 sites)
-
Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, United States -
Sidney and Lois Eskenazi Hospital
Indianapolis, Indiana, United States
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.